Research News and Research

RSS

Democrats' challenge: Finding perfect pitch for health overhaul message

With the health law repeal front and center this week, Democrats will attempt to refine their message on the measure's merits. The battle on the House floor could be a fresh opportunity to sell the sweeping legislation. To this end, the Secretary of Health and Human Services will issue a report today that quantifies the number of Americans who have preexisting conditions and would benefit from the law's protections.

18 Jan 2011

House vote on health repeal the first step in GOP re-do strategy

The politically charged Wednesday vote on repealing the health overhaul will mark the first step for Republicans in their effort to use a variety of legislative tools to undo the new federal health law. Meanwhile, almost immediately after the vote, House committees will begin considering targeted parts of health law. But some news outlets check the facts regarding a key part of the GOP argument against the measure — that it is a job killer.

18 Jan 2011

Few opt for vaccine to prevent painful shingles, NPR reports

[T]he fact is only about 10% of the 50 million people who should get the vaccine actually have. … The vaccine is expensive — $160 a shot, plus an administration fee.

18 Jan 2011

SurgiCount Safety-Sponge System helps eliminate occurrence of retained surgical sponges: Study

Results of a multi-year, independent clinical research study on retained surgical sponges published in the February edition of The Joint Commission Journal on Quality and Patient Safety show that the institution implementing the SurgiCount Safety-Sponge® System eliminated the occurrence of retained surgical sponges and the costs associated with these preventable surgical errors.

18 Jan 2011

Poll shows opposition to health law easing as advocates, lawmakers take positions before house vote

A new Associated Press-GfK poll shows the strong emotions against President Barack Obama's health overhaul may be subsiding. Meanwhile, even as the industry's trade groups remain somewhat neutral on the law's future, pre-repeal groups are stepping up lobbying efforts.

18 Jan 2011

Medical mistakes, doctor ratings gain state-level attention

In Wisconsin, the issue of access to reports on medical mistakes is part of a bill being considered in the state legislature. In Minnesota, physicians are seeking a delay to the plan to provide ratings based on cost and quality.

18 Jan 2011

Viewpoints: Next step after health law repeal effort; Refuting 'job-killing' claims; Mental health care

The continuing resolution that extended funding for the federal government until Mar. 4 gives us an opportunity to include language in the appropriations that fund the rest of this fiscal year — and must be passed to avoid a government shutdown. The language would prohibit any funds from being used to implement or enforce Obamacare (Rep. Steve King, 1/18).

18 Jan 2011

Studies offer insights into end-of-life directives

News reports focus on how doctors' religious beliefs and U.S. laws impact decisions made in end-of-life care.

18 Jan 2011

Clinipace Worldwide achieves over 800% revenue growth since 2008

Clinipace Worldwide, a global digital clinical research organization (dCRO), announced today that it recently closed its best year to date, achieving over 800% revenue growth since 2008. The company more than doubled its revenues in 2010 over the prior year, attributable to 16 new projects awarded from 12 new clients.

18 Jan 2011

Roundup: Calif., Fla. differ on health law; Texas Gov. on Medicaid 'flexibility'; Ariz. mental health

While Republicans open debate Tuesday on repealing health reform, leaders in California are sitting down to a completely different discussion: how they can most aggressively implement the new law and remain among the Obama administration's model states on the reform — without stumbling over the significant challenges that stand in their way (Kliff, 1/18).

18 Jan 2011

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $1.11 in the third quarter of fiscal 2011 after taking a charge for a new product licensing fee of $66.1 million or $0.23 per share, net of tax.

18 Jan 2011

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Harbor BioSciences, Inc., a leader in the development of a proprietary class of adrenal steroid hormones as novel pharmaceuticals, announced it has licensed the research and development and commercialization rights for three of its products, exclusively in the People's Republic of China and Hong Kong, to China State Institute of Pharmaceutical Industry (CIPI).

18 Jan 2011

Cardiac surgery market to reach over $4.4 billion by 2017

According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, percutaneous aortic valve replacement (PAVR) and percutaneous mitral valve repair (PMVR) devices are expected to enter the U.S. market in 2011 and grow to almost $1.3 billion by 2017.

18 Jan 2011

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

Mirna Therapeutics, Inc., a leading developer of microRNA (miRNA)-based therapeutics, announced today the publication of new data in the journal Nature Medicine describing the role of the tumor suppressor miRNA, miR-34, in preventing cancer stem cell development. The published results reveal that miR-34 is commonly down-regulated in prostate cancer stem cells and that this down-regulation is essential for cancer stem cell viability.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Wisepower acquires Unidym

Arrowhead Research Corporation today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company. Upfront consideration to Unidym shareholders consists of Wisepower stock and convertible bonds valued at US $5,000,000 with certain restrictions as to timing of stock sales.

18 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Alexza completes FDA review for AZ-004 NDA

Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.

18 Jan 2011

First Edition: January 18, 2011

Today's headlines feature reports about the upcoming repeal vote in the House as well as news about a government report that attempts to quantify the number of Americans who have preexisting conditions.

18 Jan 2011

Ingenuity and Erasmus enter next-generation sequencing disease research collaboration

Ingenuity® Systems, a leading provider of information solutions for life science researchers, and Erasmus Medical Center, jointly announced a scientific collaboration using next-generation sequencing (NGS) for disease research.

18 Jan 2011

Research News and Research

Democrats' challenge: Finding perfect pitch for health overhaul message

House vote on health repeal the first step in GOP re-do strategy

Few opt for vaccine to prevent painful shingles, NPR reports

SurgiCount Safety-Sponge System helps eliminate occurrence of retained surgical sponges: Study

Poll shows opposition to health law easing as advocates, lawmakers take positions before house vote

Medical mistakes, doctor ratings gain state-level attention

Viewpoints: Next step after health law repeal effort; Refuting 'job-killing' claims; Mental health care

Studies offer insights into end-of-life directives

Clinipace Worldwide achieves over 800% revenue growth since 2008

Roundup: Calif., Fla. differ on health law; Texas Gov. on Medicaid 'flexibility'; Ariz. mental health

Forest Laboratories third quarter net sales increase 6.7% to $1,063.9 million

Harbor Biosciences signs development agreements for HE2000, HE3235 and HE3286 with CIPI

Cardiac surgery market to reach over $4.4 billion by 2017

New data on role of miR-34 tumor suppressor in preventing cancer stem cell development

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Wisepower acquires Unidym

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

Alexza completes FDA review for AZ-004 NDA

First Edition: January 18, 2011

Ingenuity and Erasmus enter next-generation sequencing disease research collaboration

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

New horizons in drug discovery: High-throughput & target-to-therapy advances

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology